We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

117 hedge funds and large institutions have $125M invested in Lineage Cell Therapeutics in 2017 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 18 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 7

122% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 18

15% more funds holding

Funds holding: 102 → 117 (+15)

3.77% more ownership

Funds ownership: 48.64% → 52.41% (+3.8%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

11% less capital invested

Capital invested by funds: $140M → $125M (-$14.9M)

Holders
117
Holders Change
+15
Holders Change %
+14.71%
% of All Funds
2.65%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
23
Increased
40
Reduced
18
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BC
Broadwood Capital
New York
+$6.72M
2
Axa
Axa
France
+$5.74M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.02M
4
Deutsche Bank
Deutsche Bank
Germany
+$1.53M
5
AG
Artal Group
Luxembourg
+$686K

Top Sellers

1
FM
Family Management
New York
-$374K
2
NFA
Nationwide Fund Advisors
Ohio
-$237K
3
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
-$164K
4
DWM
Destination Wealth Management
California
-$162K
5
Group One Trading
Group One Trading
Illinois
-$62.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Swiss National Bank
26
Swiss National Bank
Switzerland
$311K +$84.9K +38,862 +31%
Charles Schwab
27
Charles Schwab
California
$310K +$95.8K +43,891 +36%
Wells Fargo
28
Wells Fargo
California
$298K +$78.5K +35,950 +29%
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$294K +$43.4K +19,879 +15%
Jacobs Levy Equity Management
30
Jacobs Levy Equity Management
New Jersey
$280K -$29.2K -13,393 -8%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$244K -$932 -427 -0.3%
Invesco
32
Invesco
Georgia
$238K -$4.14K -1,894 -1%
V
33
Veritable
Delaware
$233K – – –
VF
34
Virtu Financial
New York
$225K +$221K +101,293 +546%
ARTA
35
A.R.T. Advisors
New York
$215K +$187K +85,476 +295%
Connor, Clark & Lunn Investment Management (CC&L)
36
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$210K -$27.7K -12,677 -10%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$194K +$182K +83,214 +422%
AllianceBernstein
38
AllianceBernstein
Tennessee
$187K +$8.24K +3,772 +4%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$185K +$215K +98,416 New
WJA
40
Williams Jones & Associates
New York
$174K – – –
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$163K – – –
CA
42
Corrado Advisors
New Jersey
$161K +$2.5K +1,143 +1%
Manulife (Manufacturers Life Insurance)
43
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$160K +$20K +9,139 +12%
JP Morgan Chase
44
JP Morgan Chase
New York
$154K +$179K +81,846 New
Barclays
45
Barclays
United Kingdom
$150K +$167K +76,447 +2,430%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$149K – – –
RJFSA
47
Raymond James Financial Services Advisors
Florida
$137K +$83.3K +38,131 +110%
SG Americas Securities
48
SG Americas Securities
New York
$134K +$125K +57,036 +402%
Ameriprise
49
Ameriprise
Minnesota
$133K -$4.27K -1,955 -3%
Commonwealth Equity Services
50
Commonwealth Equity Services
Massachusetts
$130K +$998 +457 +0.7%
1
2
3 4 5

LCTX Hedge Fund Activity: Q4 2017 in Review

117 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2017, worth a combined $125M — down 11% from $140M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new LCTX positions and 7 closed out — a net gain of 16 holders — while 40 added to existing stakes and 18 trimmed.

The largest buyer was Broadwood Capital, adding an estimated $6.72M. The largest seller was Family Management, cutting an estimated $374K.

  • 117 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2017, up from 102 in Q3 2017.
  • Funds reported $125M of Lineage Cell Therapeutics stock for Q4 2017, down 11% quarter-over-quarter.
  • 23 funds opened new Lineage Cell Therapeutics positions in Q4 2017 and 7 closed out, a net change of +16 holders.
  • The largest Lineage Cell Therapeutics buyer in Q4 2017 was Broadwood Capital, an estimated $6.72M added.
  • The largest Lineage Cell Therapeutics seller in Q4 2017 was Family Management, an estimated $374K sold.

Based on aggregated 13F filings for Q4 2017.